Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Verastem, Inc.
Revolution Medicines, Inc.
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
NantCell, Inc.
Vanderbilt-Ingram Cancer Center
Humanetics Corporation
University of Pittsburgh
Case Comprehensive Cancer Center
Acrotech Biopharma Inc.
University of Texas Southwestern Medical Center
Milton S. Hershey Medical Center
Dartmouth-Hitchcock Medical Center
Georgetown University
Holy Cross Hospital, Florida
Radiation Therapy Oncology Group
UNC Lineberger Comprehensive Cancer Center
Rutgers, The State University of New Jersey
Amgen
Vanderbilt-Ingram Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
University of Alabama at Birmingham
Northwestern University
Northwestern University